Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-07-26

Clinical Trial Update: Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin [Phase 4]

View source ↗

Summary

Phase 4 trial comparing tolerability of MetroGel 1% versus Finacea 15% on split-face in healthy skin; results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Finacea 15% (azelaic acid)
  • MetroGel 1% (metronidazole)

Snippet

Sponsor: Galderma R&D | Conditions: Skin Manifestations | Phase 4 | Status: COMPLETED | Results posted: 2011-07-26